XML 87 R71.htm IDEA: XBRL DOCUMENT v3.20.4

Fair Value of Financial Instruments (Tables) (Brooklyn ImmunoTherapeutics, LLC)

9 Months Ended

Sep. 30, 2020

Brooklyn Immunotherapeutics, LLC [Member]

Schedule of Fair Value of Liabilities

The following tables summarize the liabilities that are measured at fair value as of September 30, 2020 and December 31, 2019:

		September 30, 2020
Description		Level 1				Level 2				Level 3
Liabilities:
Contigent consideration			-				-				870,000
Total		$	-			$	-			$	870,000

		December 31, 2019
Description		Level 1				Level 2				Level 3
Liabilities:
Contigent consideration			-				-				870,000
Total		$	-			$	-			$	870,000

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: